Bristol Myers to merge scientific, clinical teams under new R&D structure
Bristol Myers to merge scientific, clinical teams under new R&D structure Nov 12 (Reuters) - Bristol Myers Squibb BMY.N said on Thursday it will combine its scientific and clinical expertise teams into an end-to-end research and development department under current Chief Medical Officer Cristian Massacesi, effective January 1, 2027.
Current Chief Research Officer Robert Plenge will leave in March 2027 after the transition.
"Bringing Research and Development together as one organization is an important step in our work to position BMS for long-term growth," said CEO Christopher Boerner
Analysts are closely watching Bristol's drug development pipeline for clues on growth
"Under Cristian's leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution," Boerner said
(Reporting by Sneha S K in Bengaluru)
((Sneha.SK@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb
See all newsAbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco
Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows
Brief: Bristol Myers Squibb Presents First Clinical Data From Two Phase 3 Studies In The Adept Program Evaluating Karxt For Psychosis Associated With Alzheimer’S Disease
Brief: Sichuan Biokin Pharmaceutical's Unit Receives Milestone Payment From Bristol-Myers Squibb
Brief: Mubadala Investment Co PJSC Reports Stake In SpaceX, Pfizer, Adobe